Remarkable response to anti-PD1 immunotherapy in refractory metastatic high-grade myxofibrosarcoma patient: A case report
Conclusion:
This case described here demonstrated that immunotherapy of PD-1 inhibitor is a promising treatment option for refractory MFS with PD-L1 positive or tumor mutational burden -high, which could contribute to effective tumor response.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Immunotherapy | Internal Medicine | Kidney Cancer | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Renal Cell Carcinoma | Sarcomas | Skin Cancer